SCHEMBL24648953

SCHEMBL24648953

CCc1ccc(CN2CCNCC2=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 2/20 0.42
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
GPR4 P46093 1/20 0.40
KCNH2 Q12809 1/20 0.40
CXCR4 P61073 2/20 0.40
TP53 P04637 1/20 0.39
ACACB O00763 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
S1PR1 P21453 1/20 0.38
S1PR5 Q9H228 1/20 0.38
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4692001 0.85 MEN1 (0.47) SMN1; SMN2MEN1KMT2APOLBALDH1A1
SCHEMBL20129619 0.83 ALDH1A1 (0.42) SMN1; SMN2MEN1KMT2APOLBALDH1A1
SCHEMBL14863940 0.83 HTR2C (0.43) SMN1; SMN2MEN1KMT2APOLBALDH1A1
SCHEMBL25271016 0.83 ALDH1A1 (0.42) SMN1; SMN2POLBALDH1A1L3MBTL1CXCR4
SCHEMBL2899901 0.83 ALDH1A1 (0.63) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL92331 0.83 L3MBTL1 (0.56) MEN1KMT2APOLBALDH1A1L3MBTL1
SCHEMBL23419850 0.83 SMN1; SMN2 (0.43) SMN1; SMN2MEN1KMT2APOLBALDH1A1
SCHEMBL20133743 0.83 GAA (0.57) SMN1; SMN2MEN1KMT2APOLBALDH1A1
Hydrochloric Acid SCHEMBL4767938 0.82 ALDH1A1 (0.61) MEN1KMT2APOLBALDH1A1L3MBTL1
Bromide SCHEMBL28426487 0.81 L3MBTL1 (0.54) MEN1KMT2APOLBALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF SILVERBACK THERAPEUTICS, INC. 2022-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220362396-A1 AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF TGFBR2, SMAD2, ACVR2A MGLL 4783/4885SMN1; SMN2 3976/4885MEN1 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.